Bourdage Becomes COO As Sandoz Shuffles Management
Chief Business Officer Carol Lynch Departs As Hayling Becomes CSO
A management reshuffle at Sandoz has seen head of biopharmaceuticals Pierre Bourdage take on the role of chief operating officer among a number of changes, as parent company Novartis continues its strategic review of the generics and biosimilars unit.
You may also be interested in...
Novartis Hikes Sandoz Sales Guide As Separation Edges Closer
Novartis reported 8% top-line growth for its Sandoz unit during the first quarter of 2023, one of the last before it is separated into a standalone company.
Generics Bulletin Editor’s Picks For Q3 2022
Looking back over the third quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from July to September that include changes in ownership on the horizon for major industry players, executive reshuffles at the top of leading companies and regulators, Generics Bulletin’s annual Top 50 and the announcement of our annual awards shortlist.
Do Sandoz’ Q2 Results Indicate US Bottom Is In Sight?
Sandoz has been able to hike its previously flat full-year annual guidance following an upward trajectory for the company, especially in Europe and the US. One analyst pondered whether this suggested the “emergence of a bottom in the US generics sector” during the second half of the year.